Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Current Leases: 2019-2025

  • Burning Rock Biotech's Current Leases was N/A to $19.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $19.3 million, marking a year-over-year change of. This contributed to the annual value of $3.4 million for FY2024, which is 176.81% up from last year.
  • Per Burning Rock Biotech's latest filing, its Current Leases stood at $19.3 million for Q2 2025, which was up 472.04% from $3.4 million recorded in Q4 2024.
  • Burning Rock Biotech's 5-year Current Leases high stood at $19.3 million for Q2 2025, and its period low was $1.2 million during Q4 2023.
  • Its 3-year average for Current Leases is $7.9 million, with a median of $3.4 million in 2024.
  • Per our database at Business Quant, Burning Rock Biotech's Current Leases surged by 644.17% in 2021 and then tumbled by 77.48% in 2023.
  • Over the past 5 years, Burning Rock Biotech's Current Leases (Quarterly) stood at $5.5 million in 2021, then declined by 1.69% to $5.4 million in 2022, then plummeted by 77.48% to $1.2 million in 2023, then surged by 176.81% to $3.4 million in 2024, then reached $19.3 million in 2025.
  • Its Current Leases stands at $19.3 million for Q2 2025, versus $3.4 million for Q4 2024 and $1.2 million for Q4 2023.